8-K 1 a15-5217_38k.htm 8-K














Date of Report (Date of earliest event reported): February 25, 2015



(Exact name of registrant as specified in its charter)







(State or other jurisdiction
of incorporation)


(Commission File Number)


(IRS Employer
Identification No.)


Perryville III Building, 53 Frontage Road, Suite 220

Hampton, New Jersey 08827

(Address of principal executive offices) (Zip Code)


(908) 200-7500

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 1.01   Entry into a Material Definitive Agreement.


On February 25, 2015, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named in Schedule A to the Underwriting Agreement (the “Underwriters”). Pursuant to the terms and conditions of the Underwriting Agreement, the Company agreed to sell 7,250,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), to the Underwriters at a price of $24.00 per share, less underwriting discounts and commissions and has granted the Underwriters an option to purchase up to an additional 1,087,500 shares of Common Stock within 30 days after the date of the Underwriting Agreement. The sale to the Underwriters is expected to close on March 3, 2015, subject to customary closing conditions.


The shares of Common Stock will be issued pursuant to a prospectus supplement dated February 25, 2015, which will be filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-192640), filed with the Securities and Exchange Commission and effective on December 3, 2013, and the related base prospectus dated December 3, 2013.


The Underwriting Agreement provides that the obligations of the Underwriters are subject to certain conditions precedent and that the Underwriters have agreed, severally and not jointly, to purchase all of the shares being sold under the Underwriting Agreement if any of the shares are purchased (other than the shares subject to the Underwriters’ option to purchase additional shares). Additionally, the Underwriting Agreement contains customary representations, warranties, and covenants by the Company and customary indemnification obligations of each of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended. In addition, subject to certain exceptions, each director and executive officer of the Company has entered into an agreement with the Underwriters not to sell, transfer or otherwise dispose of securities of the Company during the 90-day period following the offering, subject to extension in certain circumstances. The Company is also restricted in its ability to sell securities during such 90-day period.


The Company estimates that the net proceeds to the Company from the offering (exclusive of proceeds from the sale of shares pursuant to any exercise of the Underwriters’ option to purchase additional shares described above) will be approximately $164.2 million after deducting the underwriting discounts and commissions, and estimated offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to fund clinical trials of its product candidates, expansion of its pipeline, expansion of its commercial team and for working capital and other general corporate purposes.


The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1. The provisions of the Underwriting Agreement, including the representations and warranties contained therein,




are not for the benefit of any party other than the parties to such agreement and are not intended as a document for investors and the public to obtain factual information about the current state of affairs of the Company. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the Commission. A copy of the opinion of Lowenstein Sandler LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.


A copy of the press release with respect to the Underwriting Agreement is furnished as Exhibit 99.1 hereto.


Item 9.01   Financial Statements and Exhibits.



Exhibit No.










Underwriting Agreement, dated February 25, 2015, by and between Celldex Therapeutics, Inc. and Jefferies LLC and Leerink Partners LLC




Opinion of Lowenstein Sandler LLP




Consent of Lowenstein Sandler LLP (included in the opinion of Lowenstein Sandler LLP as Exhibit 5.1)




Press Release, dated February 25, 2015






Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.








 Date: February 26, 2015


/s/ Avery W. Catlin






Avery W. Catlin



Title: Senior Vice President and



Chief Financial Officer